In vivo effects of the pure aryl hydrocarbon receptor antagonist GNF-351 after oral administration are limited to the gastrointestinal tract

Zhong Ze Fang, Kristopher W. Krausz, Kenjiro Nagaoka, Naoki Tanaka, Krishne Gowda, Shantu G. Amin, Gary H. Perdew, Frank J. Gonzalez

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background and Purpose GNF-351 is a potent aryl hydrocarbon receptor (AHR) antagonist that inhibits dioxin response element-dependent and independent activities. Here, the absorption, metabolism and in vivo AHR antagonist activity of GNF-351 were investigated. Experimental Approach LC-MS metabolomics was used to analyse GNF-351 metabolism in vitro and in vivo. Recombinant drug-metabolizing enzymes were employed to determine the enzymes involved in GNF-351 metabolism. Analysis of target AHR genes was performed to investigate the inhibitory effects of GNF-351 towards AHR activation. Key Results Several phase I metabolites were generated after GNF-351 was incubated with microsomes from human or mouse liver and intestine, including two oxidized GNF-351 and one tri-demethylated GNF-351. Poor absorption from the intestine resulted in no detectable levels of GNF-351 in mouse serum (0-6 h) and urine (24 h) and almost all GNF-351 was found in the faeces after 24 h. Analysis of faeces further revealed all the in vitro phase I metabolites. Novel metabolites were detected, including one di-oxidized GNF-351, two oxidized and tri-demethylated GNF-351, one dehydrogenated product of oxidized GNF-351, and one sulfation product of di-oxidized GNF-351. Cytochromes P450 were demonstrated to be the major enzymes involved in metabolism of GNF-351. After oral administration to mice, GNF-351 readily inhibited β-naphthoflavone-induced AHR activation in ileum and colon, but not that in the liver. Conclusion and Implications While poor absorption and extensive metabolism after oral administration limited the in vivo effects of the pure AHR antagonist GNF-351 in liver, it could be used to inhibit AHR activation in intestine and colon.

Original languageEnglish
Pages (from-to)1735-1746
Number of pages12
JournalBritish Journal of Pharmacology
Volume171
Issue number7
DOIs
Publication statusPublished - Apr 1 2014

Keywords

  • AHR antagonist
  • GNF-351
  • absorption
  • metabolic map

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'In vivo effects of the pure aryl hydrocarbon receptor antagonist GNF-351 after oral administration are limited to the gastrointestinal tract'. Together they form a unique fingerprint.

  • Cite this

    Fang, Z. Z., Krausz, K. W., Nagaoka, K., Tanaka, N., Gowda, K., Amin, S. G., Perdew, G. H., & Gonzalez, F. J. (2014). In vivo effects of the pure aryl hydrocarbon receptor antagonist GNF-351 after oral administration are limited to the gastrointestinal tract. British Journal of Pharmacology, 171(7), 1735-1746. https://doi.org/10.1111/bph.12576